Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.37 |
| ▸ | FEN1 | P39748 | 3/20 | 0.37 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991685 | 0.82 | ALOX5AP (0.41) | ALOX5APFEN1SLC6A4OPRM1GABRA5 | |
| SCHEMBL2986975 | 0.82 | OPRM1 (0.44) | ALOX5APFEN1OPRM1 | |
| SCHEMBL2996094 | 0.80 | SLC1A5 (0.42) | SLC1A5OPRM1 | |
| Hydrochloric Acid SCHEMBL2991791 | 0.79 | SLC1A5 (0.41) | SLC1A5OPRM1 | |
| SCHEMBL2994213 | 0.79 | ALOX5AP (0.41) | ALOX5APFEN1SLC6A4OPRM1GABRA5 | |
| SCHEMBL14027095 | 0.78 | ALOX5AP (0.41) | ALOX5APFEN1SLC6A4OPRM1GABRA5 | |
| SCHEMBL2995077 | 0.76 | OPRM1 (0.46) | ALOX5APFEN1OPRM1GABRA5 | |
| Hydrochloric Acid SCHEMBL2988673 | 0.75 | OPRM1 (0.45) | ALOX5APFEN1OPRM1GABRA5 | |
| SCHEMBL2984251 | 0.74 | KEAP1 (0.46) | ALOX5APFEN1OPRM1GABRA5HPGDS | |
| SCHEMBL2983657 | 0.73 | BCHE (0.47) | SLC1A5SLC6A4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278442-B2 | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders | PROSIDION LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | OPRM1, OPRK1, OPRD1 | ALOX5AP 1990/4885FEN1 4869/4885SLC1A5 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.